Somapacitan: complete guide

Somapacitan is a long-acting growth hormone analog first approved by FDA as Sogroya in 2020. This guide covers its structure, mechanism, labeled uses, trials and warnings.

Complete guide6 min read

Key takeaway

FDA first approved somapacitan as Sogroya on August 28, 2020, for adults with growth hormone deficiency. The label now also covers four pediatric conditions. Its molecular weight is 23,305.10 g/mol. In the pediatric trial, height velocity was 11.2 cm per year with Sogroya and 11.7 cm per year with a somatropin comparator.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Sogroya on August 28, 2020.” (this article)
ClassGrowth hormone axis
Body systemsEndocrine & metabolism
Studies cited1 in this article · 1 across 1 article on Somapacitan
Related productsGHRH analogs and GH secretagogues

Somapacitan is a long-acting form of human growth hormone. It has one amino acid swapped and a side chain that binds albumin in the blood. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Somapacitan is a prescription growth hormone analog sold as Sogroya by Novo Nordisk. Its label covers adult growth hormone deficiency and growth failure or short stature in children aged 2.5 years and older with several conditions. Binding to albumin slows its elimination. The label has no boxed warning.

Vitrapep does not sell somapacitan; this page is a reference summary of published research and regulatory information.

What is somapacitan?

Somapacitan (full U.S. name somapacitan-beco) is a modified version of human growth hormone (GH). The Sogroya label describes a protein part of 191 amino acids “with a single substitution in the amino acid backbone (L101C).” That means a leucine at position 101 is replaced by a cysteine. An albumin-binding side chain is attached at that spot. The label says it “consists of an albumin binder and a hydrophilic spacer” (Sogroya label, 2026).

Is it a peptide? Its backbone is a single chain of amino acids, so it is a polypeptide. At 191 amino acids, FDA rules class it as a protein, defined as more than 40 amino acids (21 CFR 600.3). Our peptide vs protein explainer covers the difference. The label gives a molecular weight of 23,305.10 g/mol; the side chain adds 1,191.39 g/mol. It is made in Escherichia coli by recombinant DNA technology.

PubChem has a “Somapacitan” record (CID 129894493) listing C54H95N13O20S2 and 1,310.5 g/mol (PubChem CID 129894493). Those values do not match the label’s full-molecule weight, so we rely on the label here.

Drugs@FDA lists the original approval of Sogroya (BLA 761156) on August 28, 2020, to Novo Nordisk (Drugs@FDA). The approval letter states that Sogroya “is indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency” (FDA approval letter, 2020).

Table 1

Somapacitan: key facts

Fact Detail
Structure type 191-amino-acid growth hormone analog (L101C) with an albumin-binding side chain
Class Long-acting human growth hormone analog (biologic)
Molecular formula Not stated in the label; the PubChem record (C54H95N13O20S2) does not match the full molecule
Molecular weight 23,305.10 g/mol (Sogroya label)
First FDA approval August 28, 2020 (Sogroya, BLA 761156)
Brand names (US) Sogroya (Novo Nordisk)

How does somapacitan work?

Somapacitan acts on the same receptor as natural GH. The label states: “Somapacitan-beco binds to a dimeric GH receptor in the cell membrane of target cells.” This starts signaling inside the cell. Some effects run through insulin-like growth factor-1 (IGF-1) made in the liver. Others come from the drug acting directly on tissues (Sogroya label, 2026).

The side chain is what makes it long-acting. Albumin is a carrier protein in the blood. The label explains that “the reversible binding to endogenous albumin delays elimination of somapacitan.” This “prolongs the in vivo half-life and duration of action.” The label gives a plasma half-life of about 2 to 3 days in adults with GH deficiency. Our half-life explainer covers the basics.

What is somapacitan approved for?

The Sogroya label lists these indications. In pediatric patients aged 2.5 years and older, it covers:

  • growth failure due to inadequate secretion of endogenous growth hormone;
  • short stature in children born small for gestational age (SGA) with no catch-up growth by 2 years of age;
  • growth failure associated with Noonan syndrome; and
  • idiopathic short stature (ISS).

In adults, it is indicated for “the replacement of endogenous GH in adults with growth hormone deficiency (GHD).” Drugs@FDA lists three supplements classed as new indications, all approved on February 27, 2026. The label revised that month includes the SGA, Noonan syndrome and ISS uses.

What did the key trials show?

Adults (REAL 1). This human phase 3 trial randomized 301 adults with GH deficiency. It compared somapacitan with placebo under double-blind conditions and with Norditropin, a somatropin product, in an open-label arm. The primary end point was change in truncal fat percentage at week 34. Somapacitan lowered truncal fat versus placebo: the estimated difference was −1.53 percentage points (95% CI, −2.68 to −0.38; P = 0.009). Truncal fat fell 1.06 points with somapacitan and rose 0.47 points with placebo (Johannsson et al., 2020). The registry record is NCT02229851.

Children (REAL 4). This randomized, open-label, active-controlled phase 3 trial enrolled 200 children with GH deficiency who had not been treated before. The comparator was Norditropin. The primary end point was annualized height velocity at week 52. It was 11.2 cm per year with Sogroya and 11.7 cm per year with somatropin. The difference was −0.5 cm per year (95% CI, −1.1 to 0.2) (Sogroya label, 2026; NCT03811535).

Noonan syndrome. A basket trial randomized 77 children with Noonan syndrome to Sogroya or somatropin. Height velocity at week 52 was 10.4 versus 9.2 cm per year, a difference of 1.2 (95% CI, 0.32 to 2.03), per the label.

What side effects does the label list?

The Sogroya label has no boxed warning. In adults with GH deficiency, it lists reactions reported in more than 2% of treated patients:

  • back pain, joint pain (arthralgia), indigestion (dyspepsia), sleep disorder and dizziness;
  • tonsillitis, peripheral edema, vomiting and adrenal insufficiency; and
  • high blood pressure, raised creatine phosphokinase, weight gain and anemia.

In children with GH deficiency, nasopharyngitis occurred in 16.7% with Sogroya and 16.2% with somatropin. Headache occurred in 12.1% versus 8.8%, and pain in an arm or leg in 9.8% versus 2.9%. The warnings cover acute critical illness, severe allergic reactions, tumors, glucose intolerance and raised pressure in the skull. They also cover fluid retention, low adrenal or thyroid function, pancreatitis and sudden death in children with Prader-Willi syndrome. Contraindications include active malignancy and severe diabetic retinopathy (Sogroya label, 2026).

What is somapacitan’s regulatory status, and how is it used in research?

Somapacitan is a prescription biologic in the United States. FDA licensed it under section 351(a) of the Public Health Service Act, per the approval letter. DailyMed lists one label, Sogroya from Novo Nordisk (DailyMed, 2026). The federal statute that restricts growth hormone distribution defines human growth hormone to include “an analogue” of somatropin (21 U.S.C. 333). The research summarized here is clinical: human trials in adults and children.

Frequently asked questions about somapacitan

Is somapacitan a peptide?

Its backbone is a 191-amino-acid polypeptide. Because it has more than 40 amino acids, FDA rules class it as a protein.

How is somapacitan different from somatropin?

Somatropin has the natural GH sequence. Somapacitan has one amino acid swapped and an albumin-binding side chain, which delays its elimination.

When was somapacitan approved?

Drugs@FDA lists the original approval of Sogroya on August 28, 2020.

Is somapacitan approved for children?

Yes. The current label covers children aged 2.5 years and older with GH deficiency, SGA, Noonan syndrome or ISS.

Does somapacitan have a boxed warning?

No. Its warnings include acute critical illness, tumors, glucose intolerance and raised pressure in the skull.

What to know now

  • Structure: 191-amino-acid GH analog (L101C) plus an albumin-binding side chain; 23,305.10 g/mol.
  • Approval: Sogroya, August 28, 2020, for adults; pediatric uses added later; prescription only.
  • Mechanism: binds the GH receptor; albumin binding delays elimination.
  • Evidence: lowered truncal fat versus placebo in adults; 11.2 vs 11.7 cm per year height velocity in children.
  • Safety: no boxed warning; warnings match other GH products.

What we’re watching

Further Sogroya label revisions on DailyMed; the label was last revised in February 2026. Related guides: somatropin, mecasermin and tesamorelin.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Novo Nordisk 2026, SOGROYA (somapacitan-beco) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: BLA 761156 (SOGROYA) . Retrieved November 17, Drugs@FDA: BLA 761156 (SOGROYA); U.S. Food and Drug Administration 2020, BLA 761156 approval letter: Sogroya (somapacitan-beco); National Center for Biotechnology Information 2026, PubChem compound summary for CID 129894493, somapacitan; Johannsson 2020, The Journal of Clinical Endocrinology & Metabolism, 105; Novo Nordisk A/S 2014; Novo Nordisk A/S 2019; U.S. National Library of Medicine 2026, DailyMed SPL listing: somapacitan; Legal Information Institute. 21 CFR § 600.3: Definitions . Cornell Law School. Retrieved November 17, 21 CFR § 600.3: Definitions; Legal Information Institute. 21 U.S. Code § 333: Penalties . Cornell Law School. Retrieved November 17, 21 U.S. Code § 333: Penalties. All 10 citations

Back to the research library

References

  1. Novo Nordisk. (2026). SOGROYA (somapacitan-beco) prescribing information (revised 2/2026). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eadd03b4-adc3-4b88-8a24-9d205c5b85aa
  2. U.S. Food and Drug Administration. Drugs@FDA: BLA 761156 (SOGROYA). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761156
  3. U.S. Food and Drug Administration. (2020, August 28). BLA 761156 approval letter: Sogroya (somapacitan-beco). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/761156Orig1s000ltr.pdf
  4. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 129894493, somapacitan. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/129894493
  5. Johannsson, G., et al. (2020). Once-weekly somapacitan is effective and well tolerated in adults with GH deficiency: A randomized phase 3 trial. The Journal of Clinical Endocrinology & Metabolism, 105(4), e1358-e1376. https://doi.org/10.1210/clinem/dgaa049
  6. Novo Nordisk A/S. (2014). Trial comparing the efficacy and safety of somapacitan (NNC0195-0092) with placebo and Norditropin FlexPro (somatropin) in adults with growth hormone deficiency (ClinicalTrials.gov ID NCT02229851). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT02229851
  7. Novo Nordisk A/S. (2019). A study in children with growth hormone deficiency comparing once-weekly somapacitan with once-daily Norditropin (REAL4) (ClinicalTrials.gov ID NCT03811535). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT03811535
  8. U.S. National Library of Medicine. (2026). DailyMed SPL listing: somapacitan. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=somapacitan
  9. Legal Information Institute. 21 CFR § 600.3: Definitions. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/cfr/text/21/600.3
  10. Legal Information Institute. 21 U.S. Code § 333: Penalties. Cornell Law School. Retrieved November 17, 2026, from https://www.law.cornell.edu/uscode/text/21/333